1
|
Exosomes-based particles as inhalable COVID-19 vaccines. BIOMEDICAL TECHNOLOGY 2023; 4. [PMCID: PMC10031725 DOI: 10.1016/j.bmt.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/24/2023]
Abstract
Coronavirus disease 2019 (COVID-19), a severely spreading pandemic, has dramatically brought physiological and economical burdens to people. Although the injectable vaccines have some achievements for coronavirus defense, they still generate accompanied pain, untoward reaction and cannot take part in mucosal immunity. Inhalable vaccines, as a safe, facile and efficient strategy, have been presented to protect body from virus by inducing robust mucosal immunity. Here, we give a perspective of an inhalable COVID-19 vaccine composed of lung-derived exosomes (a type of virus-like particle) conjugated with viral receptor-binding domain. The lung-derived exosomes act as carriers, such inhalable particles successfully reach at lung and reveal wider distribution and longer retention on respiratory mucosa. In addition, such vaccines induce the high production of specific antibodies and T cells in lung, significantly protecting host against coronavirus invasion. It is conceived that inhalable virus-like particles with long-term stability wound open a new avenue for vaccines delivery and further achieve vaccine popularization to against with COVID-19 pandemic.
Collapse
|
2
|
Wijesundara YH, Herbert FC, Kumari S, Howlett T, Koirala S, Trashi O, Trashi I, Al-Kharji NM, Gassensmith JJ. Rip it, stitch it, click it: A Chemist's guide to VLP manipulation. Virology 2022; 577:105-123. [PMID: 36343470 DOI: 10.1016/j.virol.2022.10.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 10/09/2022] [Accepted: 10/19/2022] [Indexed: 11/06/2022]
Abstract
Viruses are some of nature's most ubiquitous self-assembled molecular containers. Evolutionary pressures have created some incredibly robust, thermally, and enzymatically resistant carriers to transport delicate genetic information safely. Virus-like particles (VLPs) are human-engineered non-infectious systems that inherit the parent virus' ability to self-assemble under controlled conditions while being non-infectious. VLPs and plant-based viral nanoparticles are becoming increasingly popular in medicine as their self-assembly properties are exploitable for applications ranging from diagnostic tools to targeted drug delivery. Understanding the basic structure and principles underlying the assembly of higher-order structures has allowed researchers to disassemble (rip it), reassemble (stitch it), and functionalize (click it) these systems on demand. This review focuses on the current toolbox of strategies developed to manipulate these systems by ripping, stitching, and clicking to create new technologies in the biomedical space.
Collapse
Affiliation(s)
- Yalini H Wijesundara
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Fabian C Herbert
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Sneha Kumari
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Thomas Howlett
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Shailendra Koirala
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Orikeda Trashi
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Ikeda Trashi
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Noora M Al-Kharji
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA
| | - Jeremiah J Gassensmith
- Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA; Department of Biomedical Engineering, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX, 75080, USA.
| |
Collapse
|
3
|
Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature. Pharmaceutics 2022; 14:pharmaceutics14061301. [PMID: 35745873 PMCID: PMC9229831 DOI: 10.3390/pharmaceutics14061301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 06/13/2022] [Accepted: 06/16/2022] [Indexed: 11/21/2022] Open
Abstract
The requirement of an undisrupted cold chain during vaccine distribution is a major economic and logistical challenge limiting global vaccine access. Modular, nanoparticle-based platforms are expected to play an increasingly important role in the development of the next-generation vaccines. However, as with most vaccines, they are dependent on the cold chain in order to maintain stability and efficacy. Therefore, there is a pressing need to develop thermostable formulations that can be stored at ambient temperature for extended periods without the loss of vaccine efficacy. Here, we investigate the compatibility of the Tag/Catcher AP205 capsid virus-like particle (cVLP) vaccine platform with the freeze-drying process. Tag/Catcher cVLPs can be freeze-dried under diverse buffer and excipient conditions while maintaining their original biophysical properties. Additionally, we show that for two model cVLP vaccines, including a clinically tested SARS-CoV-2 vaccine, freeze-drying results in a product that once reconstituted retains the structural integrity and immunogenicity of the original material, even following storage under accelerated heat stress conditions. Furthermore, the freeze-dried SARS-CoV-2 cVLP vaccine is stable for up to 6 months at ambient temperature. Our study offers a potential solution to overcome the current limitations associated with the cold chain and may help minimize the need for low-temperature storage.
Collapse
|
4
|
Nkanga C, Ortega-Rivera OA, Shin MD, Moreno-Gonzalez MA, Steinmetz NF. Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate. Biomacromolecules 2022; 23:1812-1825. [PMID: 35344365 PMCID: PMC9003890 DOI: 10.1021/acs.biomac.2c00112] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 03/09/2022] [Indexed: 01/09/2023]
Abstract
Cowpea mosaic virus (CPMV) is a potent immunogenic adjuvant and epitope display platform for the development of vaccines against cancers and infectious diseases, including coronavirus disease 2019. However, the proteinaceous CPMV nanoparticles are rapidly degraded in vivo. Multiple doses are therefore required to ensure long-lasting immunity, which is not ideal for global mass vaccination campaigns. Therefore, we formulated CPMV nanoparticles in injectable hydrogels to achieve slow particle release and prolonged immunostimulation. Liquid formulations were prepared from chitosan and glycerophosphate (GP) before homogenization with CPMV particles at room temperature. The formulations containing high-molecular-weight chitosan and 0-4.5 mg mL-1 CPMV gelled rapidly at 37 °C (5-8 min) and slowly released cyanine 5-CPMV particles in vitro and in vivo. Importantly, when a hydrogel containing CPMV displaying severe acute respiratory syndrome coronavirus 2 spike protein epitope 826 (amino acid 809-826) was administered to mice as a single subcutaneous injection, it elicited an antibody response that was sustained over 20 weeks, with an associated shift from Th1 to Th2 bias. Antibody titers were improved at later time points (weeks 16 and 20) comparing the hydrogel versus soluble vaccine candidates; furthermore, the soluble vaccine candidates retained Th1 bias. We conclude that CPMV nanoparticles can be formulated effectively in chitosan/GP hydrogels and are released as intact particles for several months with conserved immunotherapeutic efficacy. The injectable hydrogel containing epitope-labeled CPMV offers a promising single-dose vaccine platform for the prevention of future pandemics as well as a strategy to develop long-lasting plant virus-based nanomedicines.
Collapse
Affiliation(s)
- Christian
Isalomboto Nkanga
- Department
of NanoEngineering, University of California
San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
| | - Oscar A. Ortega-Rivera
- Department
of NanoEngineering, University of California
San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
- Center
for Nano-ImmunoEngineering, University of
California San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
| | - Matthew D. Shin
- Department
of NanoEngineering, University of California
San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
- Center
for Nano-ImmunoEngineering, University of
California San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
| | - Miguel A. Moreno-Gonzalez
- Department
of NanoEngineering, University of California
San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
- Center
for Nano-ImmunoEngineering, University of
California San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
| | - Nicole F. Steinmetz
- Department
of NanoEngineering, University of California
San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
- Department
of Bioengineering, University of California
San Diego, 9500 Gilman
Dr., La Jolla, California 92039, United States
- Department
of Radiology, University of California San
Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
- Center
for Nano-ImmunoEngineering, University of
California San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
- Moores
Cancer Center, University of California
San Diego, 9500 Gilman
Dr., La Jolla, California 92039, United States
- Institute
for Materials Discovery and Design, University
of California San Diego, 9500 Gilman Dr., La Jolla, California 92039, United States
| |
Collapse
|
5
|
Koellhoffer EC, Mao C, Beiss V, Wang L, Fiering SN, Boone CE, Steinmetz NF. Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model. Mol Pharm 2022; 19:592-601. [PMID: 34978197 PMCID: PMC9207558 DOI: 10.1021/acs.molpharmaceut.1c00681] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Viral immunotherapies are being recognized in cancer treatment, with several currently approved or undergoing clinical testing. While contemporary approaches have focused on oncolytic viral therapies, our efforts center on the development of plant virus-based cancer immunotherapies. In a previous work, we demonstrated the potent efficacy of the cowpea mosaic virus (CPMV), a plant virus that does not replicate in animals, applied as an in situ vaccine. CPMV is an immunostimulatory drug candidate, and intratumoral administration remodels the tumor microenvironment leading to activation of local and systemic antitumor immunity. Efficacy has been demonstrated in multiple tumor mouse models and canine cancer patients. As wild-type CPMV is infectious toward various legumes and because shedding of infectious virus from patients may be an agricultural concern, we developed UV-inactivated CPMV (termed inCPMV) which is not infectious toward plants. We report that as a monotherapy, wild-type CPMV outperforms inCPMV in mouse models of dermal melanoma or disseminated colon cancer. Efficacy of inCPMV is less than that of CPMV and similar to that of RNA-free CPMV. Immunological investigation using knockout mice shows that inCPMV does not signal through TLR7 (toll-like receptor); structure-function studies indicate that the RNA is highly cross-linked and therefore unable to activate TLR7. Wild-type CPMV signals through TLR2, -4, and -7, whereas inCPMV more closely resembles RNA-free CPMV which signals through TLR2 and -4 only. The structural features of inCPMV explain the increased potency of wild-type CPMV through the triple pronged TLR activation. Strikingly, when inCPMV is used in combination with an anti-OX40 agonist antibody (administered systemically), exceptional efficacy was demonstrated in a bilateral B16F10 dermal melanoma model. Combination therapy, with in situ vaccination applied only into the primary tumor, controlled the progression of the secondary, untreated tumors, with 10 out of 14 animals surviving for at least 100 days post tumor challenge without development of recurrence or metastatic disease. This study highlights the potential of inCPMV as an in situ vaccine candidate and demonstrates the power of combined immunotherapy approaches. Strategic immunocombination therapies are the formula for success, and the combination of in situ vaccination strategies along with therapeutic antibodies targeting the cancer immunity cycle is a particularly powerful approach.
Collapse
Affiliation(s)
- Edward C Koellhoffer
- Department of Radiology, University of California, San Diego, La Jolla, California 92093, United States
| | - Chenkai Mao
- Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire 03755, United States
| | - Veronique Beiss
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, United States
| | - Lu Wang
- Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States
| | - Steven N Fiering
- Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire 03755, United States
- Norris Cotton Cancer Center, Geisel School of Medicine and Dartmouth Hitchcock Medical System, Lebanon, New Hampshire 03755, United States
| | - Christine E Boone
- Department of Radiology, University of California, San Diego, La Jolla, California 92093, United States
| | - Nicole F Steinmetz
- Department of Radiology, University of California, San Diego, La Jolla, California 92093, United States
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, United States
- Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States
- Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, United States
- Center for Nano-ImmunoEngineering, University of California, San Diego, La Jolla, California 92093, United States
- Institute for Materials Design and Discovery, University of California, San Diego, La Jolla, California 92093, United States
| |
Collapse
|
6
|
Virus-Like Particles as Preventive and Therapeutic Cancer Vaccines. Vaccines (Basel) 2022; 10:vaccines10020227. [PMID: 35214685 PMCID: PMC8879290 DOI: 10.3390/vaccines10020227] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 01/27/2022] [Accepted: 01/28/2022] [Indexed: 12/04/2022] Open
Abstract
Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native virus structure without being infectious. VLPs, similarly to wild type viruses, are able to efficiently target and activate dendritic cells (DCs) triggering the B and T cell immunities. Therefore, VLPs hold great promise for the development of effective and affordable vaccines in infectious diseases and cancers. Vaccine formulations based on VLPs, compared to other nanoparticles, have the advantage of incorporating multiple antigens derived from different proteins. Moreover, such antigens can be functionalized by chemical modifications without affecting the structural conformation or the antigenicity. This review summarizes the current status of preventive and therapeutic VLP-based vaccines developed against human oncoviruses as well as cancers.
Collapse
|
7
|
Ortega-Rivera OA, Shukla S, Shin MD, Chen A, Beiss V, Moreno-Gonzalez MA, Zheng Y, Clark AE, Carlin AF, Pokorski JK, Steinmetz NF. Cowpea Mosaic Virus Nanoparticle Vaccine Candidates Displaying Peptide Epitopes Can Neutralize the Severe Acute Respiratory Syndrome Coronavirus. ACS Infect Dis 2021; 7:3096-3110. [PMID: 34672530 PMCID: PMC8547496 DOI: 10.1021/acsinfecdis.1c00410] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Indexed: 12/28/2022]
Abstract
The development of vaccines against coronaviruses has focused on the spike (S) protein, which is required for the recognition of host-cell receptors and thus elicits neutralizing antibodies. Targeting conserved epitopes on the S protein offers the potential for pan-beta-coronavirus vaccines that could prevent future pandemics. We displayed five B-cell epitopes, originally identified in the convalescent sera from recovered severe acute respiratory syndrome (SARS) patients, on the surface of the cowpea mosaic virus (CPMV) and evaluated these formulations as vaccines. Prime-boost immunization of mice with three of these candidate vaccines, CPMV-988, CPMV-1173, and CPMV-1209, elicited high antibody titers that neutralized the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro and showed an early Th1-biased profile (2-4 weeks) transitioning to a slightly Th2-biased profile just after the second boost (6 weeks). A pentavalent slow-release implant comprising all five peptides displayed on the CPMV elicited anti-S protein and epitope-specific antibody titers, albeit at a lower magnitude compared to the soluble formulations. While the CPMV remained intact when released from the PLGA implants, processing results in loss of RNA, which acts as an adjuvant. Loss of RNA may be a reason for the lower efficacy of the implants. Finally, although the three epitopes (988, 1173, and 1209) that were found to be neutralizing the SARS-CoV were 100% identical to the SARS-CoV-2, none of the vaccine candidates neutralized the SARS-CoV-2 in vitro suggesting differences in the natural epitope perhaps caused by conformational changes or the presence of N-linked glycans. While a cross-protective vaccine candidate was not developed, a multivalent SARS vaccine was developed. The technology discussed here is a versatile vaccination platform that can be pivoted toward other diseases and applications that are not limited to infectious diseases.
Collapse
Affiliation(s)
- Oscar A. Ortega-Rivera
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
| | - Sourabh Shukla
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
| | - Matthew D. Shin
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
| | - Angela Chen
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
| | - Veronique Beiss
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
| | - Miguel A. Moreno-Gonzalez
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
| | - Yi Zheng
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
| | - Alex E. Clark
- Department of Medicine, University of
California-San Diego, La Jolla, California 92039, United
States
| | - Aaron F. Carlin
- Department of Medicine, University of
California-San Diego, La Jolla, California 92039, United
States
| | - Jonathan K. Pokorski
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
- Institute for Materials Discovery and Design,
University of California-San Diego, La Jolla, California
92039, United States
| | - Nicole F. Steinmetz
- Department of NanoEngineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Center for Nano-ImmunoEngineering,
University of California-San Diego, La Jolla, California
92039, United States
- Institute for Materials Discovery and Design,
University of California-San Diego, La Jolla, California
92039, United States
- Department of Bioengineering, University
of California-San Diego, La Jolla, California 92039, United
States
- Department of Radiology, University of
California-San Diego, La Jolla, California 92039, United
States
- Moores Cancer Center, University of
California-San Diego, La Jolla, California 92039, United
States
| |
Collapse
|
8
|
Hu H, Steinmetz NF. Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine. Cancers (Basel) 2021; 13:2909. [PMID: 34200802 PMCID: PMC8230452 DOI: 10.3390/cancers13122909] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 05/21/2021] [Accepted: 06/07/2021] [Indexed: 11/16/2022] Open
Abstract
To develop a human epidermal growth factor receptor-2 (HER2)-specific cancer vaccine, using a plant virus-like particle (VLP) platform. Copper-free click chemistry and infusion encapsulation protocols were developed to prepare VLPs displaying the HER2-derived CH401 peptide epitope, with and without Toll-like receptor 9 (TLR9) agonists loaded into the interior cavity of the VLPs; Physalis mottle virus (PhMV)-based VLPs were used. After prime-boost immunization of BALB/c mice through subcutaneous administration of the vaccine candidates, sera were collected and analyzed by enzyme-linked immunosorbent assay (ELISA) for the CH401-specific antibodies; Th1 vs. Th2 bias was determined by antibody subtyping and splenocyte assay. Efficacy was assessed by tumor challenge using DDHER2 tumor cells. We successful developed two VLP-based anti-HER2 vaccine candidates-PhMV-CH401 vs. CpG-PhMV-CH401; however, the addition of the CpG adjuvant did not confer additional immune priming. Both VLP-based vaccine candidates elicited a strong immune response, including high titers of HER2-specific immunoglobulins and increased toxicity of antisera to DDHER2 tumor cells. DDHER2 tumor growth was delayed, leading to prolonged survival of the vaccinated vs. naïve BALB/C mice. The PhMV-based anti-HER2 vaccine PhMV-CH401, demonstrated efficacy as an anti-HER2 cancer vaccine. Our studies highlight that VLPs derived from PhMV are a promising platform to develop cancer vaccines.
Collapse
Affiliation(s)
- He Hu
- Department of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, USA;
| | - Nicole F. Steinmetz
- Department of NanoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, USA;
- Department of Bioengineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, USA
- Department of Radiology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, USA
- Center for Nano Immuno-Engineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, USA
- Moores Cancer Center, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, USA
- Institute for Materials Discovery and Design, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92039, USA
| |
Collapse
|
9
|
Nkanga CI, Steinmetz NF. The pharmacology of plant virus nanoparticles. Virology 2021; 556:39-61. [PMID: 33545555 PMCID: PMC7974633 DOI: 10.1016/j.virol.2021.01.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 01/20/2021] [Accepted: 01/21/2021] [Indexed: 12/14/2022]
Abstract
The application of nanoparticles for medical purposes has made enormous strides in providing new solutions to health problems. The observation that plant virus-based nanoparticles (VNPs) can be repurposed and engineered as smart bio-vehicles for targeted drug delivery and imaging has launched extensive research for improving the therapeutic and diagnostic management of various diseases. There is evidence that VNPs are promising high value nanocarriers with potential for translational development. This is mainly due to their unique features, encompassing structural uniformity, ease of manufacture and functionalization by means of expression, chemical biology and self-assembly. While the development pipeline is moving rapidly, with many reports focusing on engineering and manufacturing aspects to tailor the properties and efficacy of VNPs, fewer studies have focused on gaining insights into the nanotoxicity of this novel platform nanotechnology. Herein, we discuss the pharmacology of VNPs as a function of formulation and route of administration. VNPs are reviewed in the context of their application as therapeutic adjuvants or nanocarrier excipients to initiate, enhance, attenuate or impede the formulation's toxicity. The summary of the data however also underlines the need for meticulous VNP structure-nanotoxicity studies to improve our understanding of their in vivo fates and pharmacological profiles to pave the way for translation of VNP-based formulations into the clinical setting.
Collapse
Affiliation(s)
| | - Nicole F Steinmetz
- Department of NanoEngineering, University of California-San Diego, La Jolla, CA, 92039, United States; Department of Bioengineering, Department of Radiology, Center for NanoImmunoEngineering, Moores Cancer Center, Institute for Materials Discovery and Design, University of California-San Diego, La Jolla, CA, 92039, United States.
| |
Collapse
|
10
|
Comas-Garcia M, Colunga-Saucedo M, Rosales-Mendoza S. The Role of Virus-Like Particles in Medical Biotechnology. Mol Pharm 2020; 17:4407-4420. [PMID: 33147978 DOI: 10.1021/acs.molpharmaceut.0c00828] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Virus-like particles (VLPs) are protein-based, nanoscale, self-assembling, cage architectures, which have relevant applications in biomedicine. They can be used for the development of vaccines, imaging approaches, drug and gene therapy delivery systems, and in vitro diagnostic methods. Today, three relevant viruses are targeted using VLP-based recombinant vaccines. VLP-based drug delivery, nanoreactors for therapy, and imaging systems are approaches under development with promising outcomes. Several VLP-based vaccines are under clinical evaluation. Herein, an updated view on the VLP-based biomedical applications is provided; advanced methods for the production, functionalization, and drug loading of VLPs are described, and perspectives for the field are identified.
Collapse
Affiliation(s)
- Mauricio Comas-Garcia
- Department of Sciences, Autonomous University of San Luis Potosi, San Luis Potosi 78295, México.,Genomic Medicine Section, Research Center for Health Sciences and Biomedicine, Autonomous University of San Luis Potosi, San Luis Potosi 78210, México.,High-Resolution Microscopy Section, Research Center for Health Sciences and Biomedicine, Autonomous University of San Luis Potosi, San Luis Potosi 78210, México
| | - Mayra Colunga-Saucedo
- Genomic Medicine Section, Research Center for Health Sciences and Biomedicine, Autonomous University of San Luis Potosi, San Luis Potosi 78210, México
| | - Sergio Rosales-Mendoza
- Departament of Chemical Sciences, Autonomous University of San Luis Potosi, San Luis Potosi 78210, México.,Biotechnology Section, Research Center for Health Sciences and Biomedicine, Autonomous University of San Luis Potosi, San Luis Potosi 78210, México
| |
Collapse
|
11
|
Shukla S, Wang C, Beiss V, Cai H, Washington T, Murray AA, Gong X, Zhao Z, Masarapu H, Zlotnick A, Fiering S, Steinmetz NF. The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine. Biomater Sci 2020; 8:5489-5503. [PMID: 32914796 PMCID: PMC8086234 DOI: 10.1039/d0bm01219j] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The immunosuppressive tumor microenvironment enables cancer to resist immunotherapies. We have established that intratumoral administration of plant-derived Cowpea mosaic virus (CPMV) nanoparticles as an in situ vaccine overcomes the local immunosuppression and stimulates a potent anti-tumor response in several mouse cancer models and canine patients. CPMV does not infect mammalian cells but acts as a danger signal that leads to the recruitment and activation of innate and subsequently, adaptive immune cells. In the present study we addressed whether other icosahedral viruses or virus-like particles (VLPs) of plant, bacteriophage and mammalian origin can be similarly employed as intratumoral immunotherapy. Our results indicate that CPMV in situ vaccine outperforms Cowpea chlorotic mottle virus (CCMV), Physalis mosaic virus (PhMV), Sesbania mosaic virus (SeMV), bacteriophage Qβ VLPs, or Hepatitis B virus capsids (HBVc). Furthermore, ex vivo and in vitro assays reveal unique features of CPMV that makes it an inherently stronger immune stimulant.
Collapse
Affiliation(s)
- Sourabh Shukla
- Department of NanoEngineering, University of California-San Diego, La Jolla, CA 92039, USA.
| | - Chao Wang
- Department of NanoEngineering, University of California-San Diego, La Jolla, CA 92039, USA.
| | - Veronique Beiss
- Department of NanoEngineering, University of California-San Diego, La Jolla, CA 92039, USA.
| | - Hui Cai
- Department of NanoEngineering, University of California-San Diego, La Jolla, CA 92039, USA.
| | - Torus Washington
- Department of NanoEngineering, University of California-San Diego, La Jolla, CA 92039, USA.
| | - Abner A Murray
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Xingjian Gong
- Department of Bioengineering, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Zhongchao Zhao
- Molecular and Cellular Biochemistry Department, Indiana University Bloomington, IN 47405, USA
| | - Hema Masarapu
- Department of Virology, Sri Venkateswara University, Tirupati 517502, India
| | - Adam Zlotnick
- Molecular and Cellular Biochemistry Department, Indiana University Bloomington, IN 47405, USA
| | - Steven Fiering
- Geisel School of Medicine, Dartmouth College, Lebanon, NH 03756, USA
| | - Nicole F Steinmetz
- Department of NanoEngineering, University of California-San Diego, La Jolla, CA 92039, USA. and Department of Bioengineering, University of California-San Diego, La Jolla, CA 92039, USA and Department of Radiology, University of California-San Diego, La Jolla, CA 92039, USA and Moores Cancer Center, University of California-San Diego, La Jolla, CA 92039, USA and Center for Nano-ImmunoEngineering, University of California-San Diego, La Jolla, CA 92039, USA
| |
Collapse
|
12
|
Abstract
Nanoparticles from natural and anthropogenic sources are abundant in the environment, thus human exposure to nanoparticles is inevitable. Due to this constant exposure, it is critically important to understand the potential acute and chronic adverse effects that nanoparticles may cause to humans. In this review, we explore and highlight the current state of nanotoxicology research with a focus on mechanistic understanding of nanoparticle toxicity at organ, tissue, cell, and biomolecular levels. We discuss nanotoxicity mechanisms, including generation of reactive oxygen species, nanoparticle disintegration, modulation of cell signaling pathways, protein corona formation, and poly(ethylene glycol)-mediated immunogenicity. We conclude with a perspective on potential approaches to advance current understanding of nanoparticle toxicity. Such improved understanding may lead to mitigation strategies that could enable safe application of nanoparticles in humans. Advances in nanotoxicity research will ultimately inform efforts to establish standardized regulatory frameworks with the goal of fully exploiting the potential of nanotechnology while minimizing harm to humans.
Collapse
Affiliation(s)
- Wen Yang
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA;
| | - Lin Wang
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA;
| | - Evan M Mettenbrink
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA;
| | - Paul L DeAngelis
- Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
| | - Stefan Wilhelm
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA; .,Institute for Biomedical Engineering, Science, and Technology (IBEST), Norman, Oklahoma 73019, USA.,Stephenson Cancer Center, Oklahoma City, Oklahoma 73104, USA
| |
Collapse
|
13
|
Chen Y, Liao Q, Chen T, Zhang Y, Yuan W, Xu J, Zhang X. Freeze-Drying Formulations Increased the Adenovirus and Poxvirus Vaccine Storage Times and Antigen Stabilities. Virol Sin 2020; 36:365-372. [PMID: 32696399 PMCID: PMC7372743 DOI: 10.1007/s12250-020-00250-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Accepted: 06/09/2020] [Indexed: 11/29/2022] Open
Abstract
Successful vaccines induce specific immune responses and protect against various viral and bacterial infections. Noninactivated vaccines, especially viral vector vaccines such as adenovirus and poxvirus vaccines, dominate the vaccine market because their viral particles are able to replicate and proliferate in vivo and produce lasting immunity in a manner similar to natural infection. One challenge of human and livestock vaccination is vaccine stability related to the antigenicity and infectivity. Freeze-drying is the typical method to maintain virus vaccine stability, while cold chain transportation is required for temperatures about 2 °C–8 °C. The financial and technological resource requirements hinder vaccine distribution in underdeveloped areas. In this study, we developed a freeze-drying formula consisting of bovine serum albumin (BSA), l-glutamic acid (L-Glu), polyethylene glycol (PEG), and dextran (DEX) to improve the thermal stability and activity of viral vaccines, including vaccinia recombinant vaccine (rTTV-OVA) and adenovirus vaccine (Ad5-ENV). We compared a panel of five different formulations (PEG: DEX: BSA: L-GLU = 50:9:0:0(#1), 50:5:4:0(#2), 50:10:9:0(#3), 50:0:0:9(#4), and 50:1:0:8(#5), respectively) and optimized the freeze-drying formula for rTTV-OVA and Ad5-ENV. We found that the freeze-drying formulations #2 and #3 could maintain rTTV-OVA infectivity at temperatures of 4 °C and 25 °C and that rTTV-OVA immunogenicity was retained during lyophilization. However, formulations #4 and #5 maintained Ad5-ENV infectivity under the same conditions, and Ad5-ENV immunogenicity had maximum retention with freeze-drying formulation #4. In summary, we developed new freeze-drying formulations that increased virus vaccine storage times and retained immunogenicity at an ambient temperature.
Collapse
Affiliation(s)
- Ye Chen
- Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 201508, China
| | - Qibin Liao
- Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 201508, China
| | - Tianyue Chen
- Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 201508, China
| | - Yuchao Zhang
- Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 201508, China
| | - Weien Yuan
- Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200000, China.
| | - Jianqing Xu
- Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 201508, China.
| | - Xiaoyan Zhang
- Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 201508, China.
| |
Collapse
|